RespireRx Pharmaceuticals Inc.

Previous efforts to provide a drug therapy for obstructive sleep apnea patients have fallen short of the finish line but Apnimed says it is getting closer to taking its daily, oral combination pill i

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements and collaborations between companies and academic or other research inst

With an estimated 30 million sufferers of obstructive sleep apnea, estimated to cost the US economy about $162bn, there is an urgent need to find an acceptable solution. During the 2018 Biotech Showca

The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between Dec. 23 and Dec. 29, 2016, divided